Aerosol medications for treatment of mucus clearance disorders

Respiratory Care

Volumn 60, Issue 6, 2015, Pages 825-829

  Rubin, Bruce K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcysteine; Bicarbonate; Cystic fibrosis; Dornase alfa; Expectorants; Mucolytics; Mucus; Sputum

Indexed keywords

ACETYLCYSTEINE; AZTREONAM; BICARBONATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLISTIMETHATE; DENUFOSOL; DORNASE ALFA; EXPECTORANT AGENT; FIBRINOLYTIC AGENT; MANNITOL; MUCIN 5AC; MUCIN 5B; MUCOLYTIC AGENT; SALBUTAMOL; TOBRAMYCIN; AEROSOL;

AEROSOL; ARTICLE; ASTHMA; BLAND AEROSOL; BRONCHIECTASIS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; HUMAN; LUNG CLEARANCE; METERED DOSE INHALER; MUCUS; MUCUS CLEARANCE DISORDER; NASAL DELIVERY; RESPIRATORY TRACT DISEASE; COUGHING; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

ADMINISTRATION, INHALATION; AEROSOLS; COUGH; EXPECTORANTS; HUMANS; LUNG DISEASES; MUCOCILIARY CLEARANCE; MUCUS;

EID: 84944737150     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.04087     Document Type: Article

References (36)

1. Kater A, Henke MO, Rubin BK. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. Ann NY Acad Sci 2007;1112:140-153.
2. Rubin BK. Mucus, phlegm, and sputum in cystic fibrosis. Respir Care 2009;54(6):726-732; discussion 732.
3. Voynow JA, Rubin BK. Mucus, mucins, and sputum. Chest 2009; 135(2):505-512.
4. Rubin BK. The role of mucus in cough research. Lung 2010;188(Suppl 1):S69-S72
5. Rubin BK. The pharmacologic approach to airway clearance: mucoactive medications. Paediatr Respir Rev 2006;7(Suppl 1):S215-S219.
6. Kallstrom TJ, AARC. Clinical practice guideline. Bland aerosol administration–2003 revision and update. Respir Care 2003;48(5):529-533.
7. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007;52(7):859-865.
8. Hoffer-Schaefer A, Rozycki HJ, Yopp MA, Rubin BK. Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with an acute respiratory tract infections. Respir Care 2014;59(5):631-636.
9. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3):229-240.
10. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, Bush A. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002;57(10):841-846.
11. Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med 2013;7(1):65-75.
12. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 2013;162(4):676-680.
13. Burrows EF, Southern KW, Noone PG. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2014;4:CD005087.
14. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004;31(1):86-91
15. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulmon Med 2004;4:13.
16. Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013;7:CD007168.
17. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996;153(2):752-760.
18. Rubin BK. Who will benefit from DNase? Pediatr Pulmonol 1999; 27(1):3-4.
19. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113(5):1329-1334.
20. O’Riordan TG, Mao W, Palmer LB, Chen JJ. Assessing the effects of racemic and single enantiomer albuterol on airway secretions in long-term intubated patients. Chest 2006;129(1):124-132.
21. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278(17):1426-1431.
22. Rubin BK, Priftis KN, Schmidt HJ, Henke MO. Secretory hyperresponsiveness and mucus hypersecretion. Chest 2014;146(2):496-507.
23. Bateman ED, Rennard S, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009;22(6):533-542.
24. Tamaoki J, Chiyotani A, Kobayashi K, Sakai N, Kanemura T, Takizawa T. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992;145(3):548-552.
25. Madsen P, Shah SA, Rubin BK. Plastic bronchitis: new insights and a classification scheme. Paediatr Respir Rev 2005;6(4):292-300.
26. Eason DE, Cox K, Moskowitz WB. Aerosolised heparin in the treatment of Fontan-related plastic bronchitis. Cardiol Young 2014;24(1): 140-142.
27. Laube BL, Links JM, LaFrance ND, Wagner HN Jr, Rosenstein BJ. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest 1989;95(4): 822-830.
28. Rubin BK. Pediatric aerosol therapy: new devices and new drugs. Respir Care 2011;56(9):1411-1421; discussion 1421-1423.
29. Rubin BK, Williams RW. Emerging aerosol drug delivery strategies: from bench to clinic. Adv Drug Deliv Rev 2014;75:141-148.
30. Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care 2010;55(7):911-921.
31. Williams R, Rubin BK. Aerosol therapy for the therapy of CF. In: Bush A, Bilton D, Hodson, M. Hodson and Geddes’ cystic fibrosis, 4th edition. London: Taylor & Francis; 2015:279-297.
32. Kassel JC, King D, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev 2010; (3):CD006821.
33. Laube BL. Devices for aerosol delivery to treat sinusitis. J Aerosol Med 2007;20(Suppl 1):S5-S17; discussion S17-S18.
34. Mainz JG, Schien C, Schiller I, Schädlich K, Koitschev A, Koitschev C, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros 2014;13(4):461-470.
35. Flume PA, Robinson KA, O’Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54(4):522-537.
36. Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2013;6:CD007923.